{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "QDEL",
  "name": "QuidelOrtho Corporation",
  "url": "https://frontierpicks.com/dossiers/QDEL/",
  "json_url": "https://frontierpicks.com/dossiers/QDEL.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Deal-rumor leg fully retraced and still unresolved: the 2026-08-06 cut (FY26 adj EPS to $0.65–0.90 from $1.80–2.00, FCF guide withdrawn) took price back to the $13.79 pre-rumor shelf, and the $14.74 close of 2026-08-21 is drift on no disclosure. Nothing is scheduled inside 30 days; an unsigned ~$1.5B point-of-care sale is the only lever on 4.3x leverage.",
  "invalidation_trigger": "A weekly close below $13.75 gives back the entire 2026-06-29 deal-rumor gap and restores the pre-rumor downtrend, with the $9.92 52-week low as the next reference. Secondary: reporting that the point-of-care sale process has lapsed, or an equity takedown off the 2026-07-17 shelf.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "medtech-diagnostics",
    "semi-foundry-equipment",
    "crypto-exchanges-financials",
    "consumer-discretionary-rotation"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "S-3ASR automatic shelf filed 2026-07-17 covering 1,000,000 shares (inducement/ESOP-related) — an issuance mechanism is on file against a levered balance sheet.",
    "FY2026 free-cash-flow guidance was withdrawn on 2026-08-06; net debt leverage 4.3x adjusted EBITDA, $2.87B total debt, $123M cash.",
    "FY2025 net loss was -$1.13B (EPS -$17.81) after a $701M non-cash goodwill impairment in Q3 2025 against the 2022 Ortho Clinical combination.",
    "CFO Micah Young (ex-Masimo) took the role effective 2026-07-06 with an inducement grant of 356,555 RSUs; CEO is Brian Blaser.",
    "52-week range $9.92–$35.38, with 68.58M shares outstanding. Single-session moves above 20% have occurred in both directions during 2026."
  ],
  "body_markdown": "\n7# QDEL — QuidelOrtho Corporation\n\n## Current Thesis\nNothing has been signed and nothing further has broken. The 2026-08-06 print cut FY2026 revenue guidance to $2.52–2.60B from $2.70–2.75B, adjusted EPS to $0.65–0.90 from $1.80–2.00, and withdrew the $100–120M free-cash-flow guide; shares fell 21.3% in the session and closed $13.75 on 2026-08-10, back at the $13.79 close of 2026-06-26 that preceded the FT/Bloomberg divestiture reports. Since then the tape has drifted to $14.30 on 2026-08-14 and $14.74 on 2026-08-21 with no new company disclosure behind it — the aggregator flow since mid-August carries only re-syndication of the 2026-08-06 release. What an investor is underwriting at this level is an unsigned point-of-care divestiture, reported on 2026-06-27 at a ~$1.5B valuation, against $2.87B of total debt, $123M of cash and 4.3x net leverage, with a China lab business that fell 23% YoY in Q2.\n\n**The narrative is dead.** The specific leg — a near-term $1.5B sale re-rating a levered equity — failed on its own terms. The 35% gap of 2026-06-29 was fully retraced by 2026-08-10, management declined to confirm the process on the 2026-08-06 call, and the earnings guide was reset roughly 60% lower on adjusted EPS in the same release. The two weeks since have added price and no information. A signed agreement would open a new leg; it would not resume this one.\n\n## Bull Case\n- **Cost-out is landing while the top line shrinks.** Q2 2026 adjusted EBITDA $129M, +21% YoY, margin 20% with ~310bps of expansion (2026-08-06 release).\n- **The quarter itself beat.** Revenue $630.9M vs $618.8M consensus and adjusted EPS $0.13 vs a $(0.05) estimate; the damage came from the forward guide, not the printed period.\n- **The equity is a thin claim on a large asset.** 68.58M shares outstanding and roughly $1.01B of market capitalisation as of 2026-08-21 (stockanalysis.com) sit against a point-of-care unit reported at ~$1.5B on 2026-06-27, with Advent International, SK Capital Partners and Archimed named as interested. A signature near that headline resets the capital structure in one step.\n- **Management left the door open on 2026-08-06.** Asked directly, CEO Brian Blaser said the company does not comment on market rumors, then added that it regularly evaluates a broad range of opportunities including portfolio opportunities.\n- **The reset guide was set with post-quarter order data in hand.** The ~2026-11-04 (est.) Q3 print is the first measurement against numbers management chose after seeing Chinese destocking, rather than against pre-season assumptions.\n\n## Bear Case\n- **China deteriorated faster than the model.** Q2 China revenue -23% YoY. The June 2026 second draft of the Chinese IVD pricing guideline removed use-case differentiation, broadened product scope, and expanded the pilot from three provinces to six; management said customers were adjusting purchasing and inventory \"more quickly and significantly than we had anticipated\" (2026-08-06 call).\n- **Withdrawing free-cash-flow guidance at 4.3x net leverage is the heaviest line in the release.** $2.87B of total debt against $123M of cash as of 2026-08-06 leaves the equity as the residual tranche.\n- **Guidance has been reset twice inside one fiscal year**, ending at a $0.65–0.90 adjusted EPS range versus $1.80–2.00 previously — a credibility discount that a single in-line quarter does not clear.\n- **The prior-year comparison is a $1.13B FY2025 net loss** (EPS -$17.81) including a $701M non-cash goodwill impairment taken in Q3 2025 against the 2022 Ortho Clinical combination.\n- **Sell-side dispersion is wide and the high end is stale.** JPMorgan cut to $11 with an Underweight rating on 2026-08-07, ~25% below the 2026-08-21 close of $14.74; Citigroup's $18 Neutral target dates from 2026-07-08 and predates the guidance cut.\n- **An issuance mechanism is already on file.** S-3ASR automatic shelf filed 2026-07-17 covering 1,000,000 shares (inducement/ESOP-related).\n\n## Setup & Price Structure\n- Reference close $14.74 on 2026-08-21, 58.3% below the $35.38 52-week high, RSI(14) 37.6. The 52-week range is $9.92–$35.38.\n- The round trip in closes: $13.79 on 2026-06-26 → a 35% gap on 2026-06-29 → $17.38 on 2026-07-17 → $13.75 on 2026-08-10 → $14.30 on 2026-08-14 → $14.74 on 2026-08-21. The retracement is complete; the drift since 2026-08-10 is roughly 7% and carries no disclosure.\n- The shares are up 24.3% over three months. That figure is measured from a late-May level underneath the June gap, so it describes the rumor spike rather than any trend now in force.\n- Two weeks of closes between $13.75 and $14.74 following a 21.3% down day is too short a sample to call a base. The $13.75 close of 2026-08-10 and the $13.79 pre-rumor mark form the only shelf the tape has defended since the cut.\n- Crowding observables, stated as observed: no earnings date falls inside 30 days; RSI below 40 with price 58% under the high shows no momentum extension; the dated headline flow has thinned to one primary broker action since the print (JPMorgan, 2026-08-07) with post-2026-08-14 items being restatements of the Q2 release. The identifiable supply-side items are the 2026-07-17 shelf and the 356,555-RSU inducement grant to CFO Micah Young effective 2026-07-06; neither is an open-market insider sale.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-08-23 to 2026-09-22 — no scheduled company event.** As of 2026-08-21 no Q3 2026 reporting date has been announced.\n- **Unscheduled (second draft dated June 2026) — final Chinese IVD pricing guideline.** Determines whether the Q2 destocking is a one-time reset or a permanent step-down in the lab consumables base.\n- **~2026-11-04 (est.) — Q3 2026 results.** Outside the 30-day window; extrapolated from the 2026-08-06 Q2 print and the 2025-11-05 Q3 2025 date, not confirmed by the company.\n\n## Elapsed catalysts\n\n- **Unscheduled (unsigned as of 2026-08-06) — definitive agreement for the point-of-care testing unit.** Reported at ~$1.5B on 2026-06-27; the only identified path to materially reducing $2.87B of debt. *(passed 20d ago)*\n\n## What Would Change Our Mind\nThe residual case rests entirely on a process no one has confirmed, so it can end without a price move at all: reporting that Advent, SK Capital or Archimed have withdrawn, a signed deal well below the ~$1.5B headline with earnouts or contingent consideration, or an equity takedown off the 2026-07-17 shelf would each remove the reason to hold the name through a 4.3x-levered balance sheet. On the tape, a weekly close below $13.75 gives back the whole 2026-06-29 gap and restores the pre-rumor downtrend, with the $9.92 52-week low as the next reference. In the other direction, the case would have to be re-opened on evidence rather than price: a signed agreement at or near ~$1.5B, or a Q3 print in which China declines by materially less than the 23% YoY posted in Q2 and the withdrawn free-cash-flow forecast is reinstated. Absent one of those, the ~2026-11-04 (est.) print is the next dated information and the intervening weeks are unpriced drift.\n\n## Correlation Notes\n- The two largest 2026 moves were company-specific: the 35% advance of 2026-06-29 came on M&A reporting (that session's Benzinga movers list ran alongside a Dow up 350 points), and the 21.3% decline followed the 2026-08-06 guidance cut. Index beta explains little of either.\n- Shared factor with IVD peers carrying Chinese lab exposure: any final volume-based-procurement pricing rule reprices the group's consumables annuity, and the June 2026 draft already expanded the pilot from three provinces to six.\n- Respiratory-season seasonality links the point-of-care line to other rapid-testing franchises; a second soft season would show up across that cohort, not in QDEL alone.\n- With $2.87B of debt at 4.3x adjusted EBITDA and no free-cash-flow forecast, the equity behaves as a levered stub — more sensitive to high-yield spread moves and refinancing conditions than a typical medtech name of comparable market capitalisation.",
  "first_seen": "2026-06-07",
  "last_analyzed": "2026-08-23T16:21:58+00:00",
  "last_synthesized": "2026-08-23",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}